title: Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
authors.forename: Lucia
authors.initials: L
authors.lastname: Llanos
authors.forename: Pablo
authors.initials: P
authors.lastname: Bellot
authors.forename: Pedro
authors.initials: P
authors.lastname: Zapater
authors.forename: Miguel
authors.initials: M
authors.lastname: Pérez-Mateo
authors.forename: Jose
authors.initials: J
authors.lastname: Such
mesh_terms: D000208:Acute Disease; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008099:Liver / Q000187:drug effects; D008103:Liver Cirrhosis / Q000150:complications* / Q000821:virology; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib